Press coverage about BioTelemetry (NASDAQ:BEAT) has trended somewhat positive on Sunday, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioTelemetry earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 47.0536879894909 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:

Shares of BioTelemetry (NASDAQ:BEAT) traded up $0.25 during trading on Friday, reaching $28.30. The company had a trading volume of 299,824 shares, compared to its average volume of 428,617. The firm has a market capitalization of $915.79, a P/E ratio of 36.28, a price-to-earnings-growth ratio of 1.54 and a beta of 0.58. The company has a current ratio of 2.03, a quick ratio of 1.91 and a debt-to-equity ratio of 0.16.

BioTelemetry (NASDAQ:BEAT) last issued its earnings results on Tuesday, August 8th. The medical research company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.02. BioTelemetry had a return on equity of 18.75% and a net margin of 21.03%. The business had revenue of $58.10 million during the quarter, compared to analyst estimates of $58.39 million. During the same period in the previous year, the company posted $0.20 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. research analysts forecast that BioTelemetry will post 0.96 EPS for the current year.

A number of analysts recently commented on BEAT shares. Zacks Investment Research lowered BioTelemetry from a “hold” rating to a “strong sell” rating in a research report on Thursday. Benchmark Co. boosted their target price on BioTelemetry from $38.00 to $44.00 and gave the company a “buy” rating in a research report on Wednesday, July 19th. Dougherty & Co boosted their target price on BioTelemetry from $37.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, August 9th. Lake Street Capital reaffirmed a “buy” rating and issued a $50.00 target price (up from $35.00) on shares of BioTelemetry in a research report on Friday, July 14th. Finally, Raymond James Financial, Inc. started coverage on BioTelemetry in a research report on Thursday, October 26th. They issued an “outperform” rating and a $37.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. BioTelemetry presently has an average rating of “Buy” and a consensus target price of $42.86.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact BioTelemetry (BEAT) Share Price” was published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at

BioTelemetry Company Profile

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Insider Buying and Selling by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.